Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THC/CBD Oral Solution for Chronic Neuropathic Pain in Multiple Sclerosis
2024-520287-34-01Phase 2Authorised
- Sponsor
- Ferraz Lynce
- Start
- Jun 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic neuropathic pain, multiple sclerosis (MS) and Muscle spasm comparing Satalliv (THC/CBD oral solution) with Matching placebo oral solution (2 arms). Primary endpoint: Change in pain intensity (NRS 0-10) between baseline and 4 weeks of optimized treatment. Planned start Jun 2025; status: authorised.
02
Drugs
nabiximols
03
Conditions
chronic neuropathic painmultiple sclerosis (MS)Muscle spasm
Beyond the preview
Go deeper on 2024-520287-34-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520287-34-01.